Sun Pharma's SPARC Signs a Research Collaboration with HitGen to Develop Therapies
Shots:
- HitGen to receive upfront & milestones and will utilize its DNA-encoded library design technology to develop therapies for Sun Pharma’s SPARC targets
- The focus of the collaboration is to combine the SPARC’s research expertise with HitGen’s DELs based screening technology to develop therapies for serious medical conditions
- HitGen’s DELs is a platform for small molecule drug discovery including 400B macrocyclic compounds developing biological targets. The company has also collaborated with other companies & foundations in North America- Europe- Asia & Africa to discover therapies & agrochemical solutions
Ref: HitGen | Image: Livemint
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com